• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 161

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a Psychedelic Informed World

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab

Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as...

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge...

Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of...

HAVN Life Enters Supply Agreement with MPB Group Inc.

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual...

Numinus Unveils New Logo and Brand Identity

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking...

Digging Up Druggable Targets: Psilocybin Efficacy in a Model of OCD

1...160161162...301Page 161 of 301

EDITOR PICKS

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a...

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©